↑ 疾患リストへ ← 戻る

 66. IgA腎症 [臨床試験数:125,薬物数:151(DrugBank:51),標的遺伝子数:30,標的パスウェイ数:36] 

Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR19000268832019-12-0128 October 2019A prospective randomized controlled trial of a new method for glucocorticoid intervention in progressive IgA nephropathyA prospective randomized controlled trial of a new method for glucocorticoid intervention in progressive IgA nephropathyIgA nephropathy1: 0.5mg/kg.d prednisolone induced remission;2:0.8mg/kg.d prednisolone induced remission ;Nephrology Department, Hangzhou Hospital of Traditional Chinese Medicine, Zhejiang ProvinceNot Recruiting1872Both1:71;2:71;Phase 0China
2NCT04014335November 201911 November 2019A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA NephropathyAn Open-Label Phase 2a Clinical Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Subjects With Primary IgA NephropathyPrimary IgA NephropathyDrug: IONIS-FB-LRxIonis Pharmaceuticals, Inc.Recruiting18 Years75 YearsAll10Phase 2Australia;Canada;New Zealand
3NCT04020328August 1, 201929 July 2019Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal InsufficiencyA Randomized, Controlled Trial to Evaluate Leflunomide Plus Low Dose Corticosteroid Therapy in Progressive IgA Nephropathy With Renal InsufficiencyGlomerulonephritis, IGA;Renal Insufficiency, ChronicDrug: Leflunomide 20 mg+prednisone 0.5mg/kg/dShenzhen Second People's HospitalNot recruiting14 Years65 YearsAll70Phase 4
4NCT03418779July 1, 201926 August 2019Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in Patients of IgA Nephropathy With High-risk of ESRDTreatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in Patients of IgA Nephropathy With High-risk of ESRDIgA Nephropathy at High Risk of Developing ESRDDrug: The Yi-Qi-Qing-Jie Herbal Compound;Drug: Immunosuppressive Agents;Other: Optimized Supportive Care;Other: Yi-Qi-Qing-Jie herbal compound placeboGuang'anmen Hospital of China Academy of Chinese Medical SciencesRecruiting18 Years70 YearsAll56Phase 2/Phase 3China
5NCT03841448April 24, 201911 November 2019A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients With IgA NephropathyIgA Nephropathy (IgAN);Berger Disease;Glomerulonephritis, IgADrug: Placebo;Drug: CemdisiranAlnylam PharmaceuticalsRecruiting18 Years65 YearsAll30Phase 2United States;Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03945318April 8, 201920 May 2019Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)A Phase 1, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA NephropathyIgA NephropathyDrug: BION-1301 Single Dose;Drug: Placebo Single Dose;Drug: BION-1301 Multiple Doses;Drug: Placebo Multiple DosesAduro Biotech, Inc.Recruiting18 Years55 YearsAll73Phase 1United Kingdom
7ChiCTR19000221002019-04-011 April 2019Evaluation of clinical efficacy of Modified Huangqi Chifeng Decoction in treating IgA Nephropathy proteinuia based on Chinese medicine pathogenesis of “deficiency-wind-stasis -toxin”Evaluation of clinical efficacy of Modified Huangqi Chifeng Decoction in treating IgA Nephropathy proteinuia based on Chinese medicine pathogenesis of “deficiency-wind-stasis -toxin”IgA nephropathyPlacebo Group:Placebo+telmisartan;Experimental group:Flavoured huangqi chifeng granules+telmisartan;Xiyuan Hospital, China Academy of Chinese Medical SciencesRecruitingBothPlacebo Group:40;Experimental group:40;Phase 4China
8NCT03468972March 201925 February 2019Effect of Immunosuppression in IgA NephropathyEffect of Immunosuppression in IgA NephropathyBiopsy-proven IgA NephropathyDrug: Immunosuppressive treatment;Other: intensive supportive careYonsei UniversityNot recruiting19 Years75 YearsAll174Phase 4Korea, Republic of
9NCT03762850December 20, 201826 August 2019A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA NephropathyA Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A NephropathyImmunoglobulin A NephropathyDrug: sparsentan;Drug: irbesartanRetrophin, Inc.Recruiting18 YearsN/AAll280Phase 3United States;Australia;Belgium;Croatia;Czechia;Estonia;France;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom
10ChiCTR18000196062018-12-0126 November 2018Effect of kunxian capsule and leflunomide on IgA nephropathyEffect of kunxian capsule and leflunomide on IgA nephropathyIgA nephropathy1:Kun-Xian Capsule;2:Leflunomide;The First Affiliated Hospital of Chengdu Medical CollegeNot Recruiting1575Both1:20;2:20;Post-marketChina
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2017-004605-41-CZ03/10/20187 January 2019Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN)A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A NephropathyImmunoglobulin A Nephropathy (IgAN)
MedDRA version: 20.0 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]
Product Name: Sparsentan
Product Code: RE-021
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Sparsentan
CAS Number: 254740-64-2
Current Sponsor code: RE-021
Other descriptive name: SPARSENTAN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Trade Name: Irbesartan tablets
Product Name: over-encapsulated Irbesartan Tablets
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Irbesartan
CAS Number: 138402-11-6
Other descriptive name: IRBESARTAN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Retrophin, Inc.AuthorisedFemale: yes
Male: yes
280Phase 3Portugal;United States;Taiwan;Estonia;Hong Kong;Spain;Lithuania;United Kingdom;Italy;France;Czech Republic;Poland;Belgium;Croatia;Australia;Germany;New Zealand;Korea, Republic of
12EUCTR2017-004605-41-ES27/09/201826 November 2018Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN)A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A NephropathyImmunoglobulin A Nephropathy (IgAN)
MedDRA version: 20.0 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]
Product Name: Sparsentan
Product Code: RE-021
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Sparsentan
CAS Number: 254740-64-2
Current Sponsor code: RE-021
Other descriptive name: SPARSENTAN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Trade Name: Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03
Product Name: over-encapsulated 150 mg Irbesartan Tablets
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Irbesartan
CAS Number: 138402-11-6
Other descriptive name: IRBESARTAN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Retrophin, Inc.AuthorisedFemale: yes
Male: yes
280Phase 3Portugal;United States;Estonia;Hong Kong;Spain;Lithuania;Turkey;Italy;United Kingdom;France;Czech Republic;Hungary;Poland;Malaysia;Belgium;Croatia;Australia;Germany;New Zealand;Korea, Republic of
13NCT03643965September 5, 201827 May 2019Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) NephropathyA Randomized, Double-blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd)Primary IgA NephropathyDrug: Nefecon;Drug: Placebo oral capsuleCalliditas Therapeutics ABRecruiting18 YearsN/AAll450Phase 3United States;Argentina;Australia;Belarus;Belgium;Canada;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom
14EUCTR2018-000075-33-SK21/06/201827 August 2018OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGANIgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Code: OMS721
Pharmaceutical Form: Solution for infusion
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use
Omeros CorporationAuthorisedFemale: yes
Male: yes
434Phase 3United States;Hungary;Slovakia;Canada;Spain;Lithuania;Australia
15EUCTR2017-004902-16-BE18/06/20184 December 2018A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy.A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd).Primary IgA nephropathy patients at risk of developing end stage renal disease
MedDRA version: 20.0 Level: LLT Classification code 10069341 Term: Berger's disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Nefecon
Product Code: Nefecon
Pharmaceutical Form: Modified-release capsule, hard
INN or Proposed INN: BUDESONIDE
CAS Number: 51333-22-3
Other descriptive name: Nefecon
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4-
Pharmaceutical form of the placebo: Modified-release capsule, hard
Route of administration of the placebo: Oral use
Calliditas Therapeutics ABAuthorisedFemale: yes
Male: yes
450Phase 3United States;Belarus;Taiwan;Greece;Finland;Spain;Turkey;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Germany;Korea, Republic of;Sweden
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16EUCTR2018-000075-33-LT15/06/201823 July 2018OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGANIgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Code: OMS721
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: OMS721
Current Sponsor code: OMS721
Other descriptive name: OMS721
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 370-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use
Omeros CorporationAuthorisedFemale: yes
Male: yes
434Phase 3United States;Hungary;Canada;Lithuania;Australia
17EUCTR2018-000075-33-HU07/06/201818 June 2018OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGANIgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Code: OMS721
Pharmaceutical Form: Solution for infusion
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use
Omeros CorporationAuthorisedFemale: yes
Male: yes
434Phase 3United States;Hungary;Canada;Australia
18EUCTR2017-004902-16-CZ04/06/201820 August 2018A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy.A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd).Primary IgA nephropathy patients at risk of developing end stage renal disease
MedDRA version: 20.0 Level: LLT Classification code 10069341 Term: Berger's disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Nefecon
Product Code: Nefecon
Pharmaceutical Form: Modified-release capsule, hard
INN or Proposed INN: BUDESONIDE
CAS Number: 51333-22-3
Other descriptive name: Nefecon
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4-
Pharmaceutical form of the placebo: Modified-release capsule, hard
Route of administration of the placebo: Oral use
Calliditas Therapeutics ABAuthorisedFemale: yes
Male: yes
450Phase 3United States;Belarus;Taiwan;Greece;Finland;Spain;Turkey;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Germany;Korea, Republic of;Sweden
19EUCTR2017-004902-16-ES09/04/201811 June 2018A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy.A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd).Primary IgA nephropathy patients at risk of developing end stage renal disease
MedDRA version: 20.0 Level: LLT Classification code 10069341 Term: Berger's disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Nefecon
Product Code: Nefecon
Pharmaceutical Form: Modified-release capsule, hard
INN or Proposed INN: BUDESONIDE
CAS Number: 51333-22-3
Other descriptive name: Nefecon
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4-
Pharmaceutical form of the placebo: Modified-release capsule, hard
Route of administration of the placebo: Oral use
Calliditas Therapeutics ABAuthorisedFemale: yes
Male: yes
450Phase 3United States;Belarus;Taiwan;Greece;Finland;Spain;Turkey;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Germany;Korea, Republic of;Sweden
20JPRN-UMIN0000320312018/04/015 November 2019The steroid internal use method for patients with IgA nephropathyThe steroid internal use method for patients with IgA nephropathy - The steroid internal use method for patients with IgA nephropathyIgA nephropathyPrednisolone 0.5mg/kg/every other day group
Prednisolone 0.25mg/kg/everyday group
Juntendo UniversityRecruiting20years-old100years-oldMale and Female100Not selectedJapan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21EUCTR2017-004902-16-SE28/03/201828 February 2019A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy.A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd).Primary IgA nephropathy patients at risk of developing end stage renal disease
MedDRA version: 20.0 Level: LLT Classification code 10069341 Term: Berger's disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Nefecon
Product Code: Nefecon
Pharmaceutical Form: Modified-release capsule, hard
INN or Proposed INN: BUDESONIDE
CAS Number: 51333-22-3
Other descriptive name: Nefecon
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4-
Pharmaceutical form of the placebo: Modified-release capsule, hard
Route of administration of the placebo: Oral use
Calliditas Therapeutics ABAuthorised Female: yes
Male: yes
450Phase 3United States;Belarus;Taiwan;Greece;Finland;Spain;Turkey;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Germany;Korea, Republic of;Sweden
22NCT03188887February 20, 20181 April 2019Treatment of IgA Nephropathy According to Renal LesionsTreatment of IgA Nephropathy According to Renal LesionsIgA NephropathyDrug: corticotherapy;Drug: Renin Angiotensin system (RAS) blockadeAssistance Publique - Hôpitaux de ParisRecruiting18 YearsN/AAll122Phase 3France
23EUCTR2017-000891-27-SE19/02/201822 October 2018A study evaluating the of safety and efficacy of LNP023 in patients with a kidney disorder called IgAN nephropathyAn adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patientsPrimary IgA Nephropathy
MedDRA version: 20.0 Level: HLGT Classification code 10029149 Term: Nephropathies System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Code: LNP023
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: not yet established
Other descriptive name:  LNP023 HYDROCHLORIDE SALT
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Code: LNP023
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: not yet established
Other descriptive name:  LNP023 HYDROCHLORIDE SALT
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Code: LNP023
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: not yet established
Other descriptive name:  LNP023 HYDROCHLORIDE SALT
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Novartis Pharma AGAuthorisedFemale: yes
Male: yes
218Phase 2United States;Taiwan;Finland;Thailand;United Kingdom;Argentina;Belgium;Singapore;Australia;Denmark;Netherlands;Germany;Norway;China;Sweden;Korea, Republic of
24NCT03608033February 16, 201811 June 2019Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) NephropathyA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)IgA NephropathyBiological: OMS721;Other: Vehicle (D5W or saline)Omeros CorporationRecruiting18 YearsN/AAll450Phase 3United States;Australia;Austria;Belgium;Bulgaria;Hungary;Lithuania;Poland;Slovakia;Spain
25NCT03373461February 7, 20184 November 2019Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by InflammationAn Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy PatientsIgA NephropathyDrug: LNP023;Drug: PlaceboNovartis PharmaceuticalsRecruiting18 YearsN/AAll118Phase 2Argentina;Australia;Belgium;China;Denmark;Finland;Germany;Netherlands;Norway;Singapore;Sweden;Taiwan;Thailand;Turkey;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26NCT03453619January 22, 201828 January 2019Phase II Study Assessing Safety and Efficacy of APL-2 in GlomerulopathiesA Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)IgA Nephropathy;Lupus Nephritis;Membranous Nephropathy;C3 Glomerulonephritis;Dense Deposit DiseaseDrug: APL-2Apellis Pharmaceuticals, Inc.Recruiting18 YearsN/AAll48Phase 2United States
27EUCTR2017-000891-27-FI09/01/20186 November 2018A study evaluating the of safety and efficacy of LNP023 in patients with a kidney disorder called IgAN nephropathyAn adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patientsPrimary IgA Nephropathy
MedDRA version: 20.0 Level: HLGT Classification code 10029149 Term: Nephropathies System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Code: LNP023
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: not yet established
Other descriptive name:  LNP023 HYDROCHLORIDE SALT
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Code: LNP023
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: not yet established
Other descriptive name:  LNP023 HYDROCHLORIDE SALT
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Code: LNP023
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: not yet established
Other descriptive name:  LNP023 HYDROCHLORIDE SALT
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Novartis Pharma AGAuthorisedFemale: yes
Male: yes
218Phase 2United States;Taiwan;Finland;Thailand;United Kingdom;Argentina;Belgium;Singapore;Australia;Denmark;Netherlands;Germany;Norway;China;Sweden;Korea, Republic of
28ChiCTR-IIR-170134872018-01-0127 November 2017A multicenter, double blind, double dummy, randomized controlled clinical study on the treatment of IgA nephropathy with Zhengqingfengtongning extantabA multicenter, double blind, double dummy, randomized controlled clinical study on the treatment of IgA nephropathy with Zhengqingfengtongning extantabIgA nephropathyExperimental group:Zhengqing Fengtongning extantab;Control group 1:Losartan Potassium Tablets;Control group 2:Losartan Potassium Tablets + Zhengqing Fengtongning extantab;The Third Xiangya Hospital of Central South UniversityRecruiting1870BothExperimental group:36;Control group 1:36;Control group 2:36;Phase 4 studyChina
29NCT03366337December 26, 201724 June 2019A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIXA Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney DiseasesIgA Nephropathy;CKD Associated With Type 1 Diabetes;Focal Segmental Glomerulosclerosis;Autosomal Dominant Polycystic KidneyDrug: Bardoxolone methyl capsulesReata Pharmaceuticals, Inc.Not recruiting18 Years65 YearsAll103Phase 2United States
30NCT03633864November 22, 20173 September 2018Fecal Microbiota Transplantation for Refractory IgA NephropathyFecal Microbiota Transplantation for Refractory IgA Nephropathy: a Prospective, Single-center, Cohort StudyIgA NephropathyBiological: Fecal microbiota transplantationFourth Military Medical UniversityRecruiting18 Years65 YearsAll30Phase 2China
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31EUCTR2016-002262-31-GB17/03/201711 December 2017A Clinical Trial to Examine the Effects of the Drug Atacicept in Patients with Nephropathy (Diabetic Kidney Disease).A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA NephropathyIgA Nephropathy
MedDRA version: 20.1 Level: PT Classification code 10061835 Term: Diabetic nephropathy System Organ Class: 10038359 - Renal and urinary disorders
MedDRA version: 20.0 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]
Product Name: Atacicept
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: Atacicept
Other descriptive name: ATACICEPT
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: range
Concentration number: 25-150
Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe
Route of administration of the placebo: Subcutaneous use
Merck KGaAAuthorisedFemale: yes
Male: yes
50Phase 2France;United States;Czech Republic;Taiwan;Belgium;Spain;Singapore;Israel;Japan;Italy;United Kingdom;Korea, Republic of
32JPRN-JapicCTI-18395621/2/201710 September 2019A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA NephropathyA Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA NephropathyIgA NephropathyIntervention name : Atacicept25mg
INN of the intervention : Atacicept
Dosage And administration of the intervention : Subject will receive Atacicept 25 milligram (mg) once weekly as a subcutaneous (SC) injection for 72 weeks.
Intervention name : Atacicept75mg
INN of the intervention : Atacicept
Dosage And administration of the intervention : Subject will receive Atacicept 75 mg once weekly as an SC injection for 72 weeks.
Intervention name : Atacicept25mg
INN of the intervention : Atacicept
Dosage And administration of the intervention : Subject will receive Atacicept 25 mg once weekly as an SC injection for 156 weeks.
Intervention name : Atacicept75mg
INN of the intervention : Atacicept
Dosage And administration of the intervention : Subject will receive Atacicept 75 mg once weekly as an SC injection for 156 weeks.
Intervention name : Atacicept150mg
INN of the intervention : Atacicept
Dosage And administration of the intervention : Subject will receive Atacicept 150 mg once weekly as an SC injection for 156 weeks.
Control intervention name : Placebo
INN of the control intervention : -
Dosage And administration of the control intervention : Subject will receive matching Placebo to atacicept once weekly as an SC injection for 72 weeks.
Control intervention name : Placebo
INN of the control intervention : -
Dosage And administration of the control intervention : Subject will receive matching Placebo to atacicept once weekly as an SC injection for 156 weeks.
Merck Biopharma Co., Ltd.Not Recruiting20BOTH60Phase 2Japan, Europe
33NCT02808429January 31, 201711 June 2019Efficacy and Safety of Atacicept in IgA NephropathyA Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA NephropathyIgA NephropathyDrug: Atacicept 25 mg;Drug: Atacicept 75 mg;Drug: Placebo;Drug: Atacicept 150 mgEMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyNot recruiting18 YearsN/AAll30Phase 2United States;Japan;United Kingdom;Germany
34EUCTR2016-004507-31-FR27/01/20178 January 2018N/AN/A - TIGERMedDRA version: 19.1 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disordersTrade Name: METHYLPREDNISOLONE MYLAN Générique
Product Name: METHYLPREDNISOLONE MYLAN Générique
Pharmaceutical Form: Powder for injection
INN or Proposed INN: Methylprednisolone
Other descriptive name: Methylprednisolone
Concentration unit: mg/kg milligram(s)/kilogram
Concentration type: range
Trade Name: PREDNISONE ARROW 20mg
Product Name: PREDNISONE ARROW 20mg
Pharmaceutical Form: Tablet
INN or Proposed INN: PREDNISONE
Other descriptive name: PREDNISONE
Concentration unit: mg milligram(s)
Concentration type: equal
Trade Name: PREDNISONE ARROW 5 mg
Product Name: PREDNISONE ARROW 5 mg
Pharmaceutical Form: Tablet
INN or Proposed INN: Prednisone 5 mg
Other descriptive name: Prednisone 5 mg
Concentration unit: mg milligram(s)
Concentration type: equal
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)AuthorisedFemale: yes
Male: yes
122Phase 3France
35ChiCTR-IOR-160101742016-12-0118 April 2017Clinical Study on Treatment of spleen and kidney Yang deficiency type of IgA nephropathy proteinuria with 'Huangqi guizhi wuwu' decoctionClinical Study on Treatment of spleen and kidney Yang deficiency type of IgA nephropathy proteinuria with 'Huangqi guizhi wuwu' decoctionIgA nephropathyBasic treatment+Valsartan Capsules treatment group:Basic treatment+Valsartan Capsules treatment ;Basic treatment+Huangqi guizhi wuwu decoction treatment group:Basic treatment+Huangqi guizhi wuwu decoction treatment;Shuguang Hospital affliliated to Shanghai Univesrity of TCMRecruiting1865BothBasic treatment+Valsartan Capsules treatment group:50;Basic treatment+Huangqi guizhi wuwu decoction treatment group:50;OtherChina
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36NCT03218852December 201616 December 2017Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA NephropathyAn Extended Follow-up of the Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced Stage IgA NephropathyIgA NephropathyDrug: prednisone and cyclophosphamide;Drug: prednisone aloneGuangdong General HospitalNot recruiting18 Years70 YearsAll133Phase 4China
37NCT02942381September 13, 201612 February 2018A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA NephropathyIgA Patients;HydroxychloroquineDrug: Hydroxychloroquine Sulfate;Drug: PlaceboPeking University First HospitalNot recruiting18 Years75 YearsAll60Phase 2China
38NCT02712697June 201611 April 2016Integrative Medicine of IgA NephropathyTreatment of Shentong Granules Plus Prednisone on Patients With Severe IgA Nephropathy(Ying-deficiency of the Liver and Kidney Pattern): a Randomized, Double-blind,Placebo-controlled Multicentre Clinical TrialPrimary IgA NephropathyDrug: WM (Shentong Granules);Drug: Hormone (prednisone)Shanghai University of Traditional Chinese MedicineRenJi Hospital;Ruijin Hospital;Shanghai 6th People's Hospital;Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;Fudan UniversityNot recruiting18 Years70 YearsBoth140N/AChina
39NCT02765594June 201616 December 2017Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA NephropathyHydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled StudyPrimary IgA NephropathyDrug: Hydroxychloroquine Sulfate;Drug: ValsartanPeking Union Medical College HospitalRecruiting18 Years60 YearsAll98Phase 4China
40NCT02981212June 201612 December 2016Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA NephropathyMulti-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA NephropathyIgA NephropathyDrug: Mycophenolate Mofetil;Drug: ACE inhibitor;Drug: Corticosteroid;Drug: ARBYonsei UniversityChong Kun Dang Pharmaceutical Corp.;Kyung Hee University Hospital at Gangdong;Kyungpook National University;Pusan National University Yangsan Hospital;Inje University;Seoul St. Mary's Hospital;Chonbuk National University HospitalRecruiting19 Years65 YearsBoth100Phase 4Korea, Republic of
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41NCT02662283May 201615 February 2016Validity and Security of Reh-acteoside Therapy for Patients of IgA NephropathyValidity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy —— A Prospective, Randomized, Controlled, Multi-Center Clinical TrialIGA NephropathyDrug: Prednisolone;Drug: Reh-acteosideSun Yat-sen UniversityNot recruiting14 Years70 YearsBoth75Phase 2/Phase 3China
42NCT02647255March 201610 September 2018Trial of Plasma Exchange for Severe Crescentic IgA NephropathyRandomized Trial of Plasma Exchange as Adjunctive Therapy for Severe Crescentic GlomerUlonephritis of IgA NEphropathy (RESCUE Study)Glomerulonephritis, IGA;Kidney Diseases;Acute Renal Insufficiency;Rapidly Progressive GlomerulonephritisProcedure: Plasma Exchange (PE);Drug: Methylprednisolone pulsePeking University First HospitalRecruiting14 Years65 YearsAll150Phase 2/Phase 3China
43NCT02682407February 201622 January 2018Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit DiseaseIgAN;Lupus Nephritis;MN;C3GBiological: OMS721;Other: Vehicle (D5W)Omeros CorporationRecruiting18 YearsN/AAll44Phase 2United States
44NCT03015974January 201628 January 2019Registry of IgA Nephropathy in Chinese ChildrenRegistry of IgA Nephropathy in Chinese ChildrenIgA Nephropathy;Proteinuria in Nephrotic Range;Immunosuppressive TreatmentDrug: Corticosteroid;Drug: Cyclophosphamide;Drug: Mycophenolate mofetil;Drug: Dipyridamole;Drug: ACE Inhibitor or Angiotensin receptor antagonistPeking University First HospitalNanjing PLA General Hospital;Beijing Children's Hospital;Central South University;The Children's Hospital of Zhejiang University School of Medicine;First Affiliated Hospital, Sun Yat-Sen University;Tongji Hospital;Hunan Children's Hospital;Shanghai Children's Hospital;Nanjing Children's Hospital;Children's Hospital of Chongqing Medical University;Shandong Provincial Hospital;Fuzhou General Hospital;Second Affiliated Hospital of Wenzhou Medical University;Children's Hospital of Hebei Province;Guangzhou Women and Children's Medical Center;Jiangxi Province Children's Hospital;Guangzhou First People's Hospital;Xian Children's Hospital;Capital Institute of Pediatrics, China;First Hospital of Jilin University;Wuhan Women and Children's Medical Center;Tianjin Children's Hospital;Chengdu Women's and Children's Central Hospital;The First People's Hospital of YunnanRecruiting1 Month18 YearsAll1200Phase 3China
45NCT02605525December 201516 December 2017Efficacy and Safety of SM101 in the Treatment of IgA NephropathyA Phase 2 Study to Assess the Efficacy and Safety of Intravenous Infusion With Human Soluble Recombinant Fc-gamma Receptor IIB (SM101/BAX 1810) in Subjects With Immunoglobulin A Nephropathy (IgAN)Immunoglobulin A NephropathyBiological: SM101;Other: PlaceboBaxalta now part of ShireNot recruiting18 YearsN/AAll0Phase 2
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
46EUCTR2015-002345-64-CZ12/11/201514 March 2016Efficacy and Safety of SM101 in the Treatment of IgA NephropathyA Phase 2 Study to Assess the Efficacy and Safety of Intravenous Infusion with Human Soluble Recombinant Fc-gamma Receptor IIB (SM101/BAX 1810) in Subjects with Immunoglobulin A Nephropathy (IgAN) - Efficacy and Safety of SM101 in the Treatment of IgA NephropathyIgA Nephropathy
MedDRA version: 18.0 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Body processes [G] - Immune system processes [G12]
Product Code: SM101
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: Not available
Current Sponsor code: SM101
Other descriptive name: human soluble recombinant Fc-gamma receptor IIB
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Concentrate for solution for infusion
Route of administration of the placebo: Intravenous use
Baxalta Innovations GmbHNot RecruitingFemale: yes
Male: yes
51Phase 2United States;Hong Kong;Czech Republic;Canada;Belgium;Denmark;Germany;United Kingdom;Sweden
47NCT02433236September 20152 November 2015Open Label Study of Fostamatinib in the Treatment of IgA NephropathyA Phase 2, Multi-Centre, Open Label Extension Study of Fostamatinib in the Treatment of IgA Nephropathy for Patients Who Participated in Study C-935788-050IGA NephropathyDrug: Fostamatinib Disodium tablet 150 mg;Drug: Fostamatinib Disodium tablet 100 mgRigel PharmaceuticalsNot recruiting18 Years72 YearsBoth0Phase 2
48ChiCTR-IPR-150067602015-08-0718 April 2017Efficacy and Safety of Tacrolimus in the Treatment of Immunogloglumin A Nephropathy: a Glucocorticoids-controlled, multicenter, randomized, open label clinical studyEfficacy and Safety of Tacrolimus in the Treatment of Immunogloglumin A Nephropathy: a Glucocorticoids-controlled, multicenter, randomized, open label clinical studyIgA nephropathyTacrolimus Group :Tacrolimus;Glucocorticoids Group :Glucocorticoids;Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang UniversityNot Recruiting1865BothTacrolimus Group :90;Glucocorticoids Group :90;Post-marketChina
49NCT02282930March 20154 March 2019Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of ProgressionAn Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of ProgressionProgressive IgA Nephropathy;ProteinuriaDrug: ACTH (Acthar) GelMayo ClinicMallinckrodtNot recruiting18 YearsN/AAll10Phase 3United States
50EUCTR2014-003402-33-SE12/02/201526 February 2018An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade.An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade.IgAN is reported as the most common glomerulonephritis worldwide. It is associated with a wide spectrum of disease severity and rate of progression of renal failure.
MedDRA version: 17.1 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: CCX168
Pharmaceutical Form: Capsule, hard
Current Sponsor code: CCX168
Other descriptive name: CCX168
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10mg per capsule-
ChemoCentryx, Inc.Not RecruitingFemale: yes
Male: yes
20Phase 2United States;Belgium;Sweden
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
51EUCTR2014-003402-33-BE09/02/201523 January 2017An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade.An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade.IgAN is reported as the most common glomerulonephritis worldwide. It is associated with a wide spectrum of disease severity and rate of progression of renal failure.
MedDRA version: 17.1 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: CCX168
Pharmaceutical Form: Capsule, hard
Current Sponsor code: CCX168
Other descriptive name: CCX168
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10mg per capsule-
ChemoCentryx, Inc.Not RecruitingFemale: yes
Male: yes
20Phase 2United States;Belgium;Sweden
52NCT02382523February 201516 December 2017Acthar on Proteinuria in IgA Nephropathy PatientsImpact of Acthar on Proteinuria and Disease Progression in IgA Nephropathy Patients With Nephrotic Range ProteinuriaIgA Nephropathy;ProteinuriaDrug: Acthar 80 unit injectionBaylor College of MedicineNot recruiting18 YearsN/AAll0Phase 4United States
53NCT02351752January 201528 December 2015Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled StudyRenal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal DiseasePrimary IgA NephropathyDrug: Hydroxychloroquine SulfateLLiuNot recruiting18 Years75 YearsBoth20Phase 4China
54NCT02052219October 201410 August 2015BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA NephropathyA Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA NephropathyIgA NephropathyDrug: Blisibimod;Drug: PlaceboAnthera PharmaceuticalsNot recruiting18 YearsN/ABoth0Phase 3
55NCT02112838October 201428 January 2019Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) NephropathyA Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA NephropathyIGA NephropathyDrug: Fostamatinib 150 mg;Drug: Fostamatinib 100 mg;Drug: PlaceboRigel PharmaceuticalsNot recruiting18 Years70 YearsAll76Phase 2United States;Austria;Germany;Hong Kong;Taiwan;United Kingdom;Singapore;Switzerland
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
56NCT03719443September 25, 201422 October 2019First in Human Study to Assess Safety of VIS649 in Healthy SubjectsA Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VIS649 Administered Intravenously in Healthy SubjectsImmunoglobulin A Nephropathy;IgAN - IgA Nephropathy;IgA NephropathyBiological: VIS649;Biological: PlaceboVisterra, Inc.Not recruiting18 Years55 YearsAll41Phase 1United States
57NCT02231125September 201421 July 2016Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyEfficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled TrialIgA NephropathyDrug: Losartan;Drug: Abelmoschus manihotChen XiangmeiJiangsu Suzhong Pharmaceutical Group Co., Ltd.Recruiting18 Years65 YearsBoth1600Phase 4China
58NCT02160132June 201416 March 2015A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes.Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial.Glomerulonephritis, IGA;Peripapillary Crescent;Necrosis;Steroid NephropathyDrug: Methylprednisolone(intravenously in the 1st-2nd-3rd month );Drug: Methylprednisolone(intravenously in the 1st-3rd-5th month)Sun Yat-sen UniversityRecruiting14 Years65 YearsBoth180Phase 2China
59NCT02187900June 201419 February 2015Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f.Phase 3 Study of Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. fIgA NephropathyDrug: Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH);Drug: Mycophenolate mofetil (MMF)Second Xiangya Hospital of Central South UniversityRecruiting16 Years65 YearsBoth300Phase 3China
60NCT01854814July 20138 January 2018The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy PatientsThe Effects of Mycophenolate Mofetil on Renal Outcomes in Patients With Advanced IgA Nephropathy: a Randomized Open-label StudyIgA NephropathyDrug: Mycophenolate mofetil;Drug: LosartanFan Fan HouRecruiting16 Years70 YearsAll232N/AChina
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
61NCT02062684June 201316 December 2017BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous AdministrationA Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA NephropathyIgA NephropathyDrug: Blisibimod;Drug: PlaceboAnthera PharmaceuticalsNot recruiting18 Years65 YearsAll57Phase 2/Phase 3Czechia;Germany;Hong Kong;Korea, Republic of;Malaysia;Philippines;Singapore;Taiwan;Thailand;United Kingdom;Canada;Czech Republic;Italy;Russian Federation;Spain
62ChiCTR-TRC-130030382013-01-0118 April 2017Mizoribine for the Treatment of Pediatric IgA NephropathyMizoribine for the Treatment of Pediatric IgA Nephropathy with Moderate Proteinuria--An open, prospective, random, multicenter studyIgA nephropathyMZR:mizoribine tablet 4 mg/kg a day (not more than 150 mg/d), qd, po + Dipyridamole, 3 mg/kg a day (not more than 25 mg at a time), tid, po;CVT:Lotensin, 0.2 mg/kg a day (not more than 10 mg/d), qd, po + + Dipyridamole, 3 mg/kg a day (not more than 25 mg at a time), tid, po;Peking University First HospitalNot Recruiting618BothMZR:60;CVT:60;Post-marketChina
63NCT01781312January 201319 February 2015Probiotics in IgA NephropathyProof-of-concept Study of Efficacy and Safety of Dietary Supplementation With Probiotics in IgAN PatientsIgA NephropathyDietary Supplement: ProTectis;Dietary Supplement: GastrusUppsala University HospitalUniversity Hospital, Linkoeping;Karolinska InstitutetNot recruiting18 YearsN/ABoth20N/ASweden
64NCT01738035December 20126 October 2015The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal DiseaseA Multicentre, Interventional Treatment, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon in Primary IgA Nephropathy Patients at Risk of End-stage Renal DiseasePrimary IgA NephropathyDrug: NEFECON;Other: PlaceboPharmalink ABNot recruiting18 YearsN/ABoth150Phase 2Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
65NCT01758120December 201216 December 2017Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA NephropathyA Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA NephropathyIgA NephropathyDrug: prednisone plus cyclophosphamide;Drug: Prednisone aloneGuangdong General HospitalNot recruiting18 Years70 YearsAll135Phase 4China
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
66EUCTR2012-001923-11-FI17/10/20124 August 2015A study to assess if two different doses of Nefecon (budesonide) compared to placebo are safe and effective in patients with primary IgA nephropathy at risk of developing end-stage renal diseaseA Multicentre, Interventional Treatment, Randomised, Double-Blind, Single Group Assignment, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon® in Primary IgA Nephropathy Patients at Risk of Developing End-Stage Renal Disease - The NEFIGAN TrialPrimary IgA nephropathy patients at risk of developing end stage renal disease
MedDRA version: 17.1 Level: LLT Classification code 10069341 Term: Berger's disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Nefecon
Pharmaceutical Form: Modified-release capsule, hard
INN or Proposed INN: BUDESONIDE
CAS Number: 51333-22-3
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4-
Pharmaceutical form of the placebo: Modified-release capsule, hard
Route of administration of the placebo: Oral use
Pharmalink ABNot RecruitingFemale: yes
Male: yes
200Czech Republic;Finland;Spain;Belgium;Denmark;Netherlands;Germany;United Kingdom;Italy;Sweden
67ChiCTR-TRC-120022282012-06-1518 April 2017The Clinical Study on the Dispelling Wind-dampness of IgA NephropathyThe Clinical Study on the Dispelling Wind-dampness of the chronic nephropathy: The Clinical Study on the Dispelling Wind-dampness of IgA Nephropathy(Multi-center, double-blind, randomized, controlled clinical trial program)IgA NephropathyTreatment group:IgA nephropathy side (granules)+TWP tablet;Control group:Chinese medicine simulation granules + The Tripterygium simulation piece;Hangzhou Hospital of Traditional Chinese MedicineNot Recruiting1665BothTreatment group:114;Control group:114;OtherChina
68NCT01560052April 201211 March 2019Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study Low Dose StudyIgA GlomerulonephritisDrug: methylprednisolone;Drug: PlaceboThe George InstitutePeking University First HospitalRecruiting18 YearsN/AAll500N/AAustralia;Canada;China;Hong Kong;India;Malaysia
69NCT02526966March 201216 December 2017Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA NephropathyMulticenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA NephropathyIgA NephropathyBiological: blood sampleCentre Hospitalier Universitaire de Saint EtienneNot recruiting18 YearsN/AAll68N/AFrance
70NCT02571842January 201219 October 2015Rituximab in Recurrent IgA NephropathyA Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation PathologyRecurrent IgA NephropathyDrug: Intravenous Rituximab;Drug: ACEI/ARB and corticosteroidsChulalongkorn UniversityRecruiting18 Years70 YearsBoth30Phase 4Thailand
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
71NCT01237028March 201119 September 2016Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System BlockersAdditive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System BlockersIgA NephropathyDrug: CalcitriolYonsei UniversityNot recruiting20 Years70 YearsBoth168N/AKorea, Republic of
72NCT01451710March 201119 February 2015The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA NephropathyThe Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA NephropathyIgA NephropathyDrug: Prednisone or PrednisoloneNanjing University School of MedicineNot recruiting18 Years65 YearsBoth30N/AChina
73ChiCTR-ONC-100011242011-01-0118 April 2017The effect and safety of mizoribine for IgA Nephropathy in childrenThe effect and safety of mizoribine for IgA Nephropathy in childrenIgA nephropathy1:mizoribine 3~5mg/kg.d;Nanjing general hospital of Nanjing military commandNot Recruiting516Both1:30;Post-marketChina
74ChiCTR-OPN-160100282011-01-0118 April 2017Effects of Tripterygium wilfordii induction therapy to IgA nephropathy patients with heavy proteinuriaEffects of Tripterygium wilfordii induction therapy to IgA nephropathy patients with heavy proteinuriaIgA nephropathyPrednisone (PRE) group:1mg/kg prednisone once daily;conventional-dose TW (CTW) group:60 mg TW daily;double-dose TW (DTW) group:?????120mg;Yancheng Third People's HospitalNot Recruiting2154BothPrednisone (PRE) group:10;conventional-dose TW (CTW) group:10;double-dose TW (DTW) group:10;Post-market
75NCT02523768January 20115 November 2018Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive TreatmentPrevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive TreatmentGlomerulonephritis;IgANDrug: ATG-F;Drug: SimulectCentre Hospitalier Universitaire de Saint EtienneNot recruiting18 Years75 YearsAll115Phase 4France
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
76NCT01224028November 201019 February 2015A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy PatientsDouble-blind, Randomized Placebo-controlled Clinical Trial for the Efficacy and Safety of a Calcineurin Inhibitor, Tacrolimus(Prograf Cap®) in Patients With Non-nephrotic Albuminuric, Normotensive IgA NephropathyIgA NephropathyDrug: Placebo;Drug: TacrolimusAstellas Pharma IncAstellas Pharma Korea, Inc.Not recruiting18 Years70 YearsBoth40Phase 2Korea, Republic of
77NCT01269021November 201011 April 2016An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN)Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.IgA Nephropathy (IgAN)Drug: mycophenolate mofetil plus lower dose of Prednisone;Drug: Prednisone in full doseZhi-Hong Liu, M.D.Not recruiting18 Years60 YearsBoth176N/AChina
78NCT01203007September 201019 February 2015Diet Intervention in Food Sensitive Patients With IgA NephropathyA Pilot Study of 6 Months Diet Intervention in Food Sensitive Patients With IgA NephropathyIGA NephropathyDietary Supplement: Tailored diet;Dietary Supplement: Low antigen content dietUppsala University HospitalUniversity Hospital, Linkoeping;Haukeland University Hospital;Smerud Medical Research International ASNot recruiting18 YearsN/ABoth40N/ANorway;Sweden
79NCT01103778July 201011 June 2018Pilot Study of Velcade® in IgA NephropathyVelcade Therapy for Severe IgA NephropathyChronic Kidney Disease;IgA NephropathyDrug: Bortezomib (Velcade®)The Rogosin InstituteWeill Medical College of Cornell UniversityNot recruiting18 YearsN/AAll11Phase 4United States
80NCT01184599June 201019 February 2015A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA NephropathyGlomerulonephritis, IGA;HypertensionDrug: aliskirenKagawa UniversityRecruiting16 Years75 YearsBoth30Phase 4Japan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
81EUCTR2009-016003-26-GB06/05/201020 March 2012RANDOMISED PILOT TRIAL OF MYFORTIC FOR THE TREATMENT OF PRIMARY PROTEINURIC GLOMERULONEPHRITIS. - GloMY - Proteinuria in glomerulonephritis : MyforticRANDOMISED PILOT TRIAL OF MYFORTIC FOR THE TREATMENT OF PRIMARY PROTEINURIC GLOMERULONEPHRITIS. - GloMY - Proteinuria in glomerulonephritis : MyforticPrimary Proteinuric Glomeruolnephritis Focal segmental glomeruloscerosis and IgA nephropathy
MedDRA version: 14.1 Level: PT Classification code 10067757 Term: Focal segmental glomerulosclerosis System Organ Class: 10038359 - Renal and urinary disorders
MedDRA version: 14.1 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders
Trade Name: Myfortic
Product Name: Myfortic 360mg Tablets
Pharmaceutical Form: Gastro-resistant tablet
INN or Proposed INN: mycophenolic acid
CAS Number: 24280-93-1
Other descriptive name: mycophenolate sodium
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 360-
Trade Name: Myfortic
Product Name: Myfortic 180mg Tablets
Pharmaceutical Form: Gastro-resistant tablet
INN or Proposed INN: mycophenolic sodium
CAS Number: 24280-93-1
Other descriptive name: mycophenolate sodium
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 180-
Product Name: Prednisolone
Pharmaceutical Form: Tablet
INN or Proposed INN: prednisolone
CAS Number: 50-24-8
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 1.0-25.0
UHB NHS Foundation TrustAuthorisedFemale: yes
Male: yes
100United Kingdom
82ChiCTR-TRC-100007762010-02-2718 April 2017A Study on the Efficacy and Safety of Telmisartan, Clopidogrelin and Leflunomide in patients with IgA nephropathyA Study on the Efficacy and Safety of Telmisartan, Clopidogrelin and Leflunomide in patients with IgA nephropathylgA nephropathy;ICD:N03.81:Telmisartan+ Clopidogrelin placebo + Leflunomide placebo ;2:Telmisartan + Clopidogrelin+ Leflunomide placebo ;3:Telmisartan + Clopidogrelin placebo + Leflunomide;4:Telmisartan + Clopidogrelin + Leflunomide;Chinese General Hospital of PLANot Recruiting1855Both1:100;2:100;3:100;4:100;Post-marketChina
83ChiCTR-TRC-100008242010-01-0118 April 2017the clinical effect of Fufang Shenyan Tablet on IgA Nephropathy patientsMulticenter, randomized, double-blind, placebo-controlled clinical research of the clinical effect of Fufang Shenyan Tablet on IgA Nephropathy patientsIgA Nephropathythe control group:The 24-hour urinary protein 0.5-2.0g: Lotensin 10mg, bid; placebos 2.5g tid; The 24-hour urinary protein 2.0-3.5g: on this basis, combined with prednisone 40mg/d; If patients with hypertension(target blood pressure <=130/80mmHg), used Lotensin 10mg bid alone control it difficultly, give Norvasc 5mg, qd~bid instead; if still poorly controlled, combined with Betaloc 12.5mg, bid;the treatment group:The 24-hour urinary protein 0.5-2.0g: Lotensin 10mg, bid; Fufang Shenyan Tablets 2.5g tid; The 24-hour urinary protein 2.0-3.5g: on this basis, combined with prednisone 40mg/d; If patients with hypertension (target blood pressure <=130/80mmHg), used Lotensin 10mg bid alone control it difficultly, give Norvasc 5mg, qd~bid instead; if still poorly controlled, combined with Betaloc 12.5mg, bid;The First Affiliated Hospital of Xi'an Jiaotong University Medical CollegeNot Recruiting1865Boththe control group:60;the treatment group:60;Post-marketChina
84ChiCTR-TRC-130037022010-01-0118 April 2017Study of Standardized Treatment of Integrative Medicine With the Severe IgA NephropathyStudy of Standardized Treatment of Integrative Medicine With the Severe IgA NephropathyIgA NephropathyExperimental Group:Chinese Herb Prescription Granule, 6g, Bid, po. 48 weeks;Placebo Comparator:Placebo of Chinese Herb Prescription Granule, 6g, Bid, po. 48 weeks plus prednisone, 0.5mg-1mg/kg/d, po. 48 weeks;Department of Nephrology, Longhua Hospital, Shanghai University of Traditional Chinese MedicineNot Recruiting1860BothExperimental Group:100;Placebo Comparator:10;OtherChina
85NCT01879514January 201019 February 2015Study of Standardized Treatment of Integrative Medicine With the Severe IgA NephropathStudy of Standardized Treatment of Integrative Medicine With the Severe IgA NephropathIgA NephropathyDrug: Chinese Herb Prescription Granule plus prednisone;Drug: PlaceboShanghai University of Traditional Chinese MedicineShanghai Sixth People's Hospital;RenJi HospitalRecruiting18 Years60 YearsBoth200N/AChina
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
86JPRN-UMIN0000028872009/12/012 April 2019A multicenter study to examine renal protection by a combination of an HMG-CoA reductase inhibitor and losartan in patients with dyslipidemia associated with IgA nephropathyIgA nephropathystatin and losartan group:
simvastatin 5mg and Losartan 50mg/day more than 3 months
statin group:
simvastatin 5mg/day more than 3 months
Fukuoka University Faculty of MedicineRecruiting20years-oldNot applicableMale and Female80Not selectedJapan
87NCT01129557September 200919 October 2017Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney DiseaseAldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney DiseaseProteinuric Kidney Disease;Diabetic Nephropathy;Hypertensive Nephrosclerosis;IgA Nephropathy;Focal Segmental Glomerulosclerosis;Glomerulopathy (Obesity-associated);Glomerulonephritis, MembranousDrug: Aliskiren;Drug: ValsartanColumbia UniversityNovartis PharmaceuticalsNot recruiting18 YearsN/AAll46Phase 4United States
88NCT00922311July 20093 August 2015Aliskiren for Proteinuric IgAN Despite Angiotensin BlockadeAliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot StudyIgA NephropathyDrug: AliskirenThe University of Hong KongQueen Mary Hospital, Hong Kong;United Christian HospitalNot recruiting18 Years70 YearsBoth25Phase 4China
89ChiCTR-TRC-090003382009-04-0118 April 2017Full dose of RASS blockade versus steroids therapy in patients with IgA nephropathyFull dose of RASS blockade versus steroids therapy in patients with IgA nephropathyIgA nephropathyGroup A:Full dose of RASS blockade (ACEI and ARB blocker);Group B:prednisone ;The First Affiliated Hospital of Zhejiang UniversityNot Recruiting1870MaleGroup A:60;Group B:60;Post-marketChina
90NCT00870493April 200919 February 2015Aliskiren for Immunoglobulin A (IgA) NephropathyThe Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over StudyIgA NephropathyDrug: Aliskiren;Drug: PlaceboChinese University of Hong KongNot recruiting18 Years65 YearsBoth22Phase 3Hong Kong
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
91NCT00856674March 200919 February 2015Safety Study of of Intravenous CCL2-LPM in Patients With IgA NephropathyA Dose-Escalating Phase I Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous OPL-CCL2-LPM in Patients With IgA NephropathyIGA Nephropathy;ProteinuriaBiological: OPL-CCL2-LPMOsprey Pharmaceuticals USA, Inc.Not recruiting18 YearsN/ABoth30Phase 1Canada
92NCT00885547March 200913 April 2015Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal UrinalysisProspective Clinical Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis.IgA NephropathyDrug: tripterygium wilfordii (TW)Nanjing University School of MedicineNot recruiting18 Years60 YearsBoth90N/AChina
93NCT00498368February 200919 October 2017Rituximab in Progressive Immunoglobulin A (IgA) NephropathyA Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA NephropathyIgA NephropathyDrug: Intravenous Rituximab;Drug: ACE/ARB;Dietary Supplement: Omega-3 Fatty Acid Fish Oil SupplementMayo ClinicOhio State University;Stanford University;University of North Carolina, Chapel Hill;Columbia University;Genentech, Inc.;BiogenNot recruiting18 Years70 YearsAll34Phase 4United States
94ChiCTR-TRC-090006072008-12-0118 April 2017Observation for Efficacy of methylprednisolone and combined therapy of methylprednisolone and mycophenolate mofetil for IgA nephropathyEfficacy Observation of methylprednisolone and combined therapy of methylprednisolone and mycophenolate mofetil for IgA nephropathyIgA nephropathyA:Methylprednisolone 0.4mg/kg * 8 weeks, reduction to 5mg / d to maintain, MMF 0.75 bid * 6 months after the reduction (weight <50kg, MMF0.5 bid);B:ethylprednisolone 0.4mg/kg*8 weeks, reduction to 5mg / d to maintain;Zhongshan Hospital of Fudan UniversityNot Recruiting1870BothA:40;B:40;Post-marketChina
95NCT00554502February 20086 October 2015Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA NephropathySupportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA NephropathyIgA NephropathyDrug: supportive therapy with: ACE-inhibitor / ARB / Statin;Drug: supportive and immunosuppressive therapyRWTH Aachen UniversityNot recruiting18 Years70 YearsBoth148Phase 3Germany
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
96EUCTR2007-000871-41-DE24/01/200810 July 2015Supportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy - STOP IgANSupportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy - STOP IgANIgA nephropathy (IgAN) as the most common type of glomerulonephritis.
MedDRA version: 16.1 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders
Product Name: Azathioprine
Pharmaceutical Form: Tablet
INN or Proposed INN: AZATHIOPRINE
CAS Number: 446-86-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Product Name: Cyclophosphamid
Pharmaceutical Form: Tablet
INN or Proposed INN: CYCLOPHOSPHAMIDE
CAS Number: 50180
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Product Name: Prednisolon
Pharmaceutical Form: Tablet
INN or Proposed INN: PREDNISOLONE
CAS Number: 50248
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 50-
Product Name: Methylprednisolon
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: METHYLPREDNISOLONE
CAS Number: 83432
Concentration unit: g gram(s)
Concentration type: equal
Concentration number: 1-
Product Name: supportive therapy
Pharmaceutical Form: Tablet
RWTH AachenNot RecruitingFemale: yes
Male: yes
148Germany
97NCT00599963January 200810 August 2015Paricalcitol for the Treatment of Immunoglobulin A NephropathyParicalcitol for the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over StudyIgA NephropathyDrug: paricalcitolChinese University of Hong KongNot recruiting18 Years65 YearsBoth0Phase 3Hong Kong;China
98NCT00549692November 200719 February 2015Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A NephropathyMinimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of IgA NephropathyIgA NephropathyDrug: Omega-3 fatty acid ethylester90Kuhnil Pharmaceutical Co., Ltd.Pronova BioPharma ASANot recruiting18 YearsN/ABoth152Phase 3Korea, Republic of
99NCT00657059September 200717 September 2018Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)A Prospective, Multicenter, Randomized Controlled Trial of Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)IgA NephropathyDrug: irbesartan;Drug: methylprednisolone (MP) or prednisone (pred);Drug: mycophenolate mofetil (MMF)Sun Yat-sen UniversityNot recruiting14 Years60 YearsAll151Phase 3China
100NCT00793585July 200719 October 2017A Controlled Study of Uric Acid on the Progression of IgA NephropathyA Prospective, Randomized Controlled Study of Uric Acid on the Progression of IgA NephropathyIgA NephropathyDrug: allopurinol;Other: continue their usual therapySun Yat-sen UniversityNot recruiting18 Years70 YearsAll40N/AChina
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
101NCT00426348May 200719 February 2015A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA NephropathyA Prospective Randomized, Controlled, Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA NephropathyGlomerulonephritis;IGA NephropathyDrug: Valsartan;Drug: Probucol;Drug: PlaceboGuangdong General HospitalNot recruiting18 Years60 YearsBoth75Phase 4China
102JPRN-UMIN0000024742007/01/012 April 2019Preventive effect of vit K, vit D and, risedronate on 3-dimensional trabecular microstructure in patients with IgA nephropathy on glucocorticoid treatmentGlucocorticoid induced osteoporosis in patients with IgA nephropathyMenatetrenone 45mg/day for 6 months
Calcitriol 0.5 microgram/day for 6 months
Risedronate 17.5mg/week for 6 months
Osaka University Hospital Department of nephrologyNot Recruiting18years-oldNot applicableMale and Female30Not applicableJapan
103JPRN-UMIN0000005932006/11/012 April 2019Randomized controlled trial of mizoribine for progressive IgA nephropathyIgA nephropathy with moderate to severe histological alterationsMethylprednisolone pulse therapy followed by oral prednisolone administration
Methylprednisolone pulse therapy followed by oral prednisolone and mizoribine administration
West Japan Study Group for Therapy of IgA NephropathyNot Recruiting15years-old60years-oldMale and Female120Not selectedJapan
104NCT00319761May 200619 February 2015Calcitriol in the Treatment of Immunoglobulin A (IgA) NephropathyThe Safety and Short-Term Efficacy of Calcitriol in the Treatment of Immunoglobulin A NephropathyIGA NephropathyDrug: CalcitriolChinese University of Hong KongNot recruiting18 Years65 YearsBoth10Phase 4Hong Kong
105ChiCTR-TRC-060000042006-01-0118 April 2017ACEi/ARB alone versus ACEi/ARB plus Steroids in the treatment of primary IgA nephropathy, a randomized multicenter controlled trialACEi/ARB alone versus ACEi/ARB plus Steroids in the treatment of primary IgA nephropathy, a randomized multicenter controlled trialprimary IgA nephropathygroup 1:treated with ACEI/ARB( ARB therapy is subjected to patients with cough after use of ACEI) Inhibace (cilazapril): start at 1.25mg/day, increase the dose by 1.25mg/day/week to 2.5-5mg/day Cozaar (losartan): 25~50mg/day, increased to 50~100mg/day Last for one year;group 2:Oral prednisone for 6 mos 0.8mg/kg/day x 8 wks Tapered 0.2mg/kg/day/mo in combination with ACEI/ARB;The First Hospital, Peking UniversityNot Recruiting1665Bothgroup 1:78;group 2:78;Post-marketChina
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
106NCT00378443January 200619 February 2015ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCTGlomerulonephritis, IGADrug: prednisone + Inhibace/Cozaar;Drug: Inhibace/CozaarPeking UniversityNot recruiting16 Years65 YearsBothN/A
107EUCTR2005-002610-37-ES05/12/200519 March 2012PILOT TRIAL OF TREATMENT OF POOR-PROGNOSIS IgA NEPHROPATHY WITH LOW EXPOSURE TO SIROLIMUS. Ensayo clínico piloto de tratamiento de la nefropatía IgA con factores de mal pronóstico con dosis bajas de sirolimusPILOT TRIAL OF TREATMENT OF POOR-PROGNOSIS IgA NEPHROPATHY WITH LOW EXPOSURE TO SIROLIMUS. Ensayo clínico piloto de tratamiento de la nefropatía IgA con factores de mal pronóstico con dosis bajas de sirolimusTo test in a pilot trial the efficacy and tolerance of sirolimus oral (at low doses) in patient to treat poor-prognosis IgA Nephropathy.Trade Name: RAPAMUNE
Product Name: SIROLIMUS
Pharmaceutical Form: Oral solution
INN or Proposed INN: Sirolimus
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 1-
Trade Name: RAPAMUNE
Product Name: SIROLIMUS
Pharmaceutical Form: Tablet
INN or Proposed INN: Sirolimus
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Trade Name: RAPAMUNE
Product Name: SIROLIMUS
Pharmaceutical Form: Tablet
INN or Proposed INN: Sirolimus
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2-
NEPHROLOGY DEPARTMENT (HOSPITAL UNIVERSITARY OF BELLVITGE)AuthorisedFemale: yes
Male: yes
30Spain
108EUCTR2005-003885-40-IT18/10/200524 July 2012ACE-inhibitors and Angiotensin two receptor antagonists in IgA nephropathy with mild proteinuria -The primary aim of the study consists in testing the hypothesis that blockade of the RAS may decrease the risk of developing adverse effects in patients with benign IgAN.Such blockade would first achieved with unique pharmacological class then shifting to the association of the two classes as soon as ineffective blockade is documented
MedDRA version: 9.1 Level: SOC Classification code 10038359 Term: Renal and urinary disorders
Product Name: Ramipril
Pharmaceutical Form: Tablet
INN or Proposed INN: Ramipril
CAS Number: 87333-19-5
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Product Name: Irbesartan
Pharmaceutical Form: Tablet
INN or Proposed INN: Irbesartan
CAS Number: 138402-11-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 300-
AZIENDA OSPEDALIERA PROVINCIALE DI LECCONot RecruitingFemale: yes
Male: yes
Italy
109NCT00767221October 200519 February 2015Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative StudyOral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative StudyIGA NephropathyDrug: BudesonidePharmalink ABArchimedes Development LtdNot recruiting18 YearsN/ABoth20Phase 2Sweden
110JPRN-C0000000062005/01/012 April 2019Lisinopril only and a combination of lisinopril and losartan for IgA nephropathy with focal mesangial proliferation in children: A randomized controlled trial of efficacy and safetyIgA nephropathy in childrenLisinopril for 2 years
Lisinopril+losartan for 2 years
Japanese Study group of Kidney Disease in ChildrenNot Recruiting2years-old18years-oldMale and Female110Not selectedJapan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
111JPRN-C0000003412004/04/012 April 2019Randomised controlled trial of multiple drugs combined therapy for diffuse IgA nephropathyRefractory IgA nephropathyPrednisolone and anti-thrombocyte and angiotensin II receptor blocker or angiotensin converting enzyme inhibitor
inhibitor
mizoribine and Prednisolone and anti thrombocyte and angiotensin II receptor blocker or angiotensin-converting enzyme
Japanese Study Group of Multiple drug therapy for IgANNot Recruiting16years-old75years-oldMale and Female60Not selectedJapan
112ChiCTR-TRC-090006302004-01-0118 April 2017Treatment of Early Immunoglobulin A Nephropathy by the Angiotensin Converting Enzyme Inhibitor Ramipril - A Randomized Controlled TrialTreatment of Early Immunoglobulin A Nephropathy by the Angiotensin Converting Enzyme Inhibitor Ramipril - A Randomized Controlled TrialIgA nephropathyTwo groups:ramipril 5 years versus no treatment;The Chinese University of Hong KongRecruiting00MaleTwo groups:60;OtherChina
113JPRN-C0000003802003/04/012 April 2019The renoprotective effects of ARB in patients with IgA nephropathy : multicenter,radomized trialIgA nephropathyARB valsartan

ACE-I enalapril
ARB therapeutic society of IgA nephropathyNot Recruiting16years-old75years-oldMale and Female400Phase 4Japan
114NCT00301600January 200319 February 2015Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA NephropathyMycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA NephropathyIGA NephropathyDrug: Mycophenolate mofetilNanjing University School of MedicineNot recruiting12 Years65 YearsBoth40N/AChina
115NCT01225445April 200219 February 2015Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled TrialTreatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled TrialBiopsy-confirmed IgA Nephropathy;Proteinuria Less Than 0.5 g Per Day;Normal Blood Pressure;Serum Creatinine Below 120 Umol/lDrug: RamiprilChinese University of Hong KongNot recruiting18 Years25 YearsBoth60Phase 3Hong Kong
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
116NCT00863252March 200219 February 2015Mycophenolate Mofetil for IgA NephropathyA Prospective, Randomized, Open Label, Case-Controlled Study on the Efficacy of Mycophenolate Mofetil for IgA Nephropathy Patients With Heavy Proteinuria Despite Angiotensin BlockadeIGA NephropathyDrug: mycophenolate mofetil;Drug: angiotensin blockadeThe University of Hong KongUnited Christian Hospital;Queen Mary Hospital, Hong KongNot recruiting18 Years70 YearsBoth40Phase 4China
117NCT00318474January 200219 October 2017Mycophenolate Mofetil (MMF) in Patients With IgA NephropathyA Randomized Controlled Trial of Mycophenolate Mofetil in Patients With IgA NephropathyIgA NephropathyDrug: Mycophenolate Mofetil (MMF);Drug: MMF Placebo;Drug: ACEi;Drug: FOSSt. Joseph's Hospital and Medical Center, PhoenixNot recruiting7 Years70 YearsAll184Phase 3United States
118JPRN-C0000003632001/08/012 April 2019A combination of prednisolone and mizoribine and a combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial prolideration in children:A randomized controlled trial of efficacy and safetyIgA nephropathy in childrenprednisolone+mizoribine for 2 years
prednisolone+mizoribine+warfarin+dipyridamole for 2 years
The Japanese Pediatric IgA Nephropathy of Treatment Study GroupNot Recruiting2years-old18years-oldMale and Female80Not selectedJapan
119NCT00006137May 200019 February 2015Pilot Study of Enalapril and Renal Function in Patients With IgA NephropathyIGA GlomerulonephritisDrug: enalaprilNational Center for Research Resources (NCRR)Stanford UniversityNot recruiting13 Years60 YearsBoth43N/A
120NCT01392833December 199919 February 2015Steroids and Azathioprine in Advanced IgANSteroids and Azathioprine in Early and Advanced IgA Nephropathy: Amendments to a Prospective Randomised Multicenter TrialIgA Nephropathy;Chronic Kidney DiseaseDrug: methylprednisolone;Drug: azathioprine;Drug: prednisoneA. Manzoni HospitalNot recruiting16 Years70 YearsBoth46Phase 3
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
121JPRN-C0000003731998/08/012 April 2019Lisinopril for IgA nephropathy with focal mesangial proliferation in childrenIgA nephropathy in childrenLisinopril for 2 yearsThe Japanese Pediatric IgA Nephropathy of Treatment Study GroupNot Recruiting2years-old18years-oldMale and Female50Not selectedJapan
122JPRN-C0000003741998/08/012 April 2019A combination of prednisolone, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial proliferation in children.IgA nephropathy in childrenprednisolone+warfarin+dipyridamole for 2 yearsThe Japanese Pediatric IgA Nephropathy of Treatment Study GroupNot Recruiting2years-old18years-oldMale and Female20Not selectedJapan
123JPRN-C0000003751998/08/012 April 2019A combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with nephrotic syndrome and diffuse mesangial proliferation in children.IgA nephropathy in childrenprednisolone+mizoribine+warfarin+dipyridamole for 2 yearsThe Japanese Pediatric IgA Nephropathy of Treatment Study GroupNot Recruiting2years-old18years-oldMale and Female20Not selectedJapan
124NCT00755859May 199819 February 2015Steroids and Azathioprine Versus Steroids Alone in IgANCorticosteroids and Azathioprine Versus Corticosteroids Alone in IgA Nephropathy: a Randomized Controlled Trial.IGA NephropathyDrug: steroids plus azathioprine;Drug: steroidsA. Manzoni HospitalNot recruiting16 Years70 YearsBoth206Phase 4Italy;Switzerland
125NCT00367562January 199619 February 2015Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA NephropathyPhase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA NephropathyIGA NephropathyDrug: ENALAPRIL VALSARTAN METHYLPREDNISONEHospital BritanicoNot recruiting21 Years70 YearsBoth20Phase 4Argentina

先頭へ